Cross-sectional investigation of the characteristics of intestinal flora in patients with carotid atherosclerotic plaque ulcer

注册号:

Registration number:

ITMCTR2100005005

最近更新日期:

Date of Last Refreshed on:

2021-03-04

注册时间:

Date of Registration:

2021-03-04

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

颈动脉粥样硬化斑块溃疡患者肠道菌群特征的横断面调查研究

Public title:

Cross-sectional investigation of the characteristics of intestinal flora in patients with carotid atherosclerotic plaque ulcer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

颈动脉粥样硬化斑块溃疡患者肠道菌群特征的横断面调查研究

Scientific title:

Cross-sectional investigation of the characteristics of intestinal flora in patients with carotid atherosclerotic plaque ulcer

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100043829 ; ChiMCTR2100005005

申请注册联系人:

王可彬

研究负责人:

吴圣贤

Applicant:

Wang Kebin

Study leader:

Wu Shengxian

申请注册联系人电话:

Applicant telephone:

+86 15801365569

研究负责人电话:

Study leader's telephone:

+86 13501382919

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wkbwangkebin@sina.com

研究负责人电子邮件:

Study leader's E-mail:

wushx@sina.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区海运仓胡同5号

研究负责人通讯地址:

北京市东城区海运仓胡同5号

Applicant address:

5 Haiyuncang Lane, Dongcheng District, Beijing, China

Study leader's address:

5 Haiyuncang Lane, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学东直门医院

Applicant's institution:

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

DZMEC-KY-2020-74

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学东直门医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/8/24 0:00:00

伦理委员会联系人:

薛婉君、薛春苗

Contact Name of the ethic committee:

Xue Wanjun, Xue Chunmiao

伦理委员会联系地址:

北京市东城区海运仓胡同5号

Contact Address of the ethic committee:

5 Haiyuncang Lane, Dongcheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学东直门医院

Primary sponsor:

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

北京市东城区海运仓胡同5号

Primary sponsor's address:

5 Haiyuncang Lane, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

具体地址:

东城区海运仓胡同5号

Institution
hospital:

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine

Address:

5 Haiyuncang Lane, Dongcheng District

经费或物资来源:

研究经费

Source(s) of funding:

Research funds

研究疾病:

颈动脉粥样硬化斑块溃疡

研究疾病代码:

Target disease:

Carotid atherosclerotic plaque ulcer

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

其它

Others

研究目的:

采用横断面调查研究方法,研究颈动脉粥样硬化斑块溃疡患者肠道菌群及中医证素分布特征。

Objectives of Study:

Use cross-sectional survey research methods to study the intestinal flora and the distribution characteristics of TCM syndrome elements in patients with carotid atherosclerotic plaque ulcer.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

暴露组: 彩色多普勒超声确诊颈动脉粥样硬化斑块溃疡者; 管腔狭窄<75%; 至少伴有一个危险因素,高血压或糖尿病或高脂血症; 年龄在40至70岁,性别不限; 病人知情同意,并签署知情同意书。 非暴露组: 彩色多普勒超声确诊颈动脉粥样硬化斑块,但没有溃疡的患者; 管腔狭窄<75%; 至少伴有一个危险因素,高血压或糖尿病或高脂血症; 年龄在40至70岁,性别不限; 病人知情同意,并签署知情同意书。

Inclusion criteria

Exposure group: Patients with carotid atherosclerotic plaque ulcer diagnosed by color Doppler ultrasound; The patients with lumen stenosis < 75% were selected; Subjects with at least one risk factor were hypertension or diabetes or hyperlipidemia. The subjects aged from 40 to 70 were not limited in gender; The patient informed consent and signed the informed consent form. Non exposure group: The patients with carotid atherosclerotic plaque but no ulcer were diagnosed by color Doppler ultrasound; Patients with lumen stenosis less than 75%; Subjects with at least one risk factor were hypertension or diabetes or hyperlipidemia. The subjects aged from 40 to 70 were not limited in gender; The patient informed consent and signed the informed consent form.

排除标准:

暴露组:排除近3个月内急性脑卒中或心肌梗死患者; 排除严重心律失常、房颤、心衰患者; 排除有严重肝、肾、造血系统、内分泌系统、呼吸系统等原发性疾病的患者; 排除大便异常的患者; 排除正在服用抗生素的患者; 排除孕妇。 非暴露组: 排除近3个月内急性脑卒中或心肌梗死患者; 排除有严重肝、肾、造血系统、内分泌系统、呼吸系统等原发性疾病的患者; 排除大便异常的患者; 排除正在服用抗生素的患者; 排除孕妇。

Exclusion criteria:

Exposure group: Patients with acute stroke or myocardial infarction in recent 3 months were excluded; Patients with severe arrhythmia, atrial fibrillation and heart failure were excluded; Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system and respiratory system were excluded; Patients with abnormal stool were excluded; Patients who were taking antibiotics were excluded; Pregnant women were excluded. Non exposure group: Patients with acute stroke or myocardial infarction in recent 3 months were excluded; Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system and respiratory system were excluded; Patients with abnormal stool were excluded; Patients who were taking antibiotics were excluded; Pregnant women were excluded.

研究实施时间:

Study execute time:

From 2020-08-24

To      2022-08-24

征募观察对象时间:

Recruiting time:

From 2021-03-04

To      2022-08-24

干预措施:

Interventions:

组别:

颈动脉粥样硬化斑块,但没有溃疡

样本量:

90

Group:

carotid atherosclerotic plaque but no ulcer

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

颈动脉粥样硬化斑块溃疡者

样本量:

90

Group:

carotid atherosclerotic plaque ulcer

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 180

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中医证素分布特征

指标类型:

主要指标

Outcome:

Distribution characteristics of TCM syndrome elements

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血生化

指标类型:

次要指标

Outcome:

Blood chemistry

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Intestinal flora

Type:

Primary indicator

测量时间点:

测量方法:

大便的宏基因组学

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 40
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成6个月内在指定网络平台共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Share raw data on designated network platforms within 6 months of trial completion

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1)填写观察表 研究者根据受试者的住院病历、原始观察记录,及时、完整、正确、清晰地填写观察表。 2)建立数据库 数据管理员在进行数据录入前,要了解观察表格各项目的内容及编码情况,将编码工作过程记录于编码本保存。数据库命名应规范、易读、易查找。并保证其正确、安全和保密。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Fill in the observation form The investigator filled out the observation form in a timely, complete, correct and clear manner based on the subjects’ hospitalization medical records and original observation records. 2. Build a database Before data entry, the data manager should understand the content and coding situation of each item in the observation form, and record the coding process in the codebook. The database naming should be standardized, easy to read and easy to find. And to ensure its accuracy, safety and confidentiality.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above